Monitoring PNI status prior to PD-L1/PD-1 inhibitor treatment may significantly improve survival rate, current preventive and treatment approaches, and enhance accurate personal management of SCLC patients. This evidence concerns the gene PDCD1 and small cell lung carcinoma.